Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

3.4%

1 terminated out of 29 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed with results

Key Signals

5 with results86% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (4)
P 1 (6)
P 2 (16)
P 4 (1)

Trial Status

Recruiting12
Completed6
Withdrawn4
Active Not Recruiting3
Unknown2
Terminated1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT01042379Phase 2Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT02834013Phase 2Active Not Recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

NCT06239272Phase 1Recruiting

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

NCT03860272Phase 1Active Not Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT06898970Phase 2RecruitingPrimary

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

NCT01303497Phase 2CompletedPrimary

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT04055220Not ApplicableRecruiting

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

NCT05799612Phase 1WithdrawnPrimary

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

NCT06440005Phase 1Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06849986Phase 2Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

NCT03331250Phase 2Active Not RecruitingPrimary

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

NCT05859074Phase 1Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT06375941RecruitingPrimary

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

NCT02625389Phase 4Completed

A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures

NCT06277154Phase 2Recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

NCT06526897Not ApplicableNot Yet Recruiting

Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

NCT04518124Phase 2CompletedPrimary

Propranolol in Angiosarcoma

NCT02584309Phase 2Completed

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Scroll to load more

Research Network

Activity Timeline